TaiMed Biologics is a leading pharmaceutical company based in Taiwan, specializing in the discovery, development, and delivery of medicines for infectious diseases. With an ESG score of 27.4, the company is considered to have medium risk. TaiMed Biologics leverages its intellectual resources to create a diverse product pipeline including TMB-365 and VRC07-523LS. The company's commitment to sustainability, governance, and environmental practices sets it apart in the biotechnology industry.